Main clinical, biological characteristics, and treatments in 70 patients with subcutaneous panniculitis-like T-cell lymphoma in the study cohort
| Patients . | n = 70 (%) . |
|---|---|
| Ethnicity | |
| Europe | 37/63 (59) |
| Asia* | 9/63 (14) |
| North Africa | 7/63 (11) |
| Sub-Saharan Africa | 4/63 (6) |
| Caribbean Islands | 3/63 (5) |
| Polynesia | 3/63 (5) |
| History of autoimmune disease | 25/68 (37) |
| Lupus erythematosus | 13/68 (19) |
| Rheumatoid arthritis | 4/68 (6) |
| Antiphospholipids syndrome | 4/68 (6) |
| Overlap syndrome | 2/68 (3) |
| Autoimmune cytopenia | 2/68 (3) |
| Autoimmune thyroiditis | 2/68 (3) |
| Autoimmune cytopenia | 2/68 (3) |
| Multiple sclerosis | 1/68 (2) |
| Alopecia areata | 1/68 (2) |
| Clinical abnormalities | |
| Lesions size | |
| 1-5 cm | 16/38 (42) |
| 5-10 cm | 12/38 (32) |
| >10 cm | 9/38 (24) |
| Morphology of the lesions | |
| Nodules | 53/61 (87) |
| Plaques | 16/61 (26) |
| Ulceration | 6/61 (10) |
| Number of lesions | |
| Single | 5/68 (7) |
| Multiple | 63/68 (93) |
| Localization of the lesions | |
| Upper limb | 36/68 (53) |
| Lower limb | 42/68 (62) |
| Trunk | 37/68 (54) |
| Head | 15/68 (22) |
| B symptoms | 46/67 (69) |
| Fever | 36/67 (54) |
| Weight loss | 19/67 (28) |
| Asthenia | 36/67 (54) |
| Lymphadenopathy | 21/66 (32) |
| Splenomegaly | 11/65 (17) |
| Hepatomegaly | 11/66 (17) |
| Biological abnormalities | |
| Hemophagocytic syndrome | 12/68 (18) |
| Auto-antibodies | 32/52 (62) |
| Anti-nuclear antibodies (titer > 1/80) | 30/52 (58) |
| Treatments | |
| Polychemotherapy† | 17/68 (25) |
| Polychemotherapy as first-line treatment | 11/68 (16) |
| Followed by an autologous stem cell transplantation | 4/68 (6) |
| Followed by an allogeneic stem cell transplantation | 1/68 (2) |
| Polychemotherapy as second-line treatment | 6/68 (9) |
| Followed by an autologous stem cell transplantation | 1/68 (2) |
| Followed by an allogeneic stem cell transplantation | 1/68 (2) |
| Immunosuppressive drug as first-line treatment | 52/68 (77) |
| Corticosteroids | 16/68 (24) |
| Corticosteroids + low-dose methotrexate | 12/68 (18) |
| Hydroxychloroquine | 8/68 (12) |
| Low-dose methotrexate | 7/68 (10) |
| Corticosteroids + hydroxychloroquine | 2/68 (3) |
| α-interferon | 2/68 (3) |
| Chloraminophene | 1/68 (2) |
| Corticosteroids + cyclosporine | 1/68 (2) |
| Patients . | n = 70 (%) . |
|---|---|
| Ethnicity | |
| Europe | 37/63 (59) |
| Asia* | 9/63 (14) |
| North Africa | 7/63 (11) |
| Sub-Saharan Africa | 4/63 (6) |
| Caribbean Islands | 3/63 (5) |
| Polynesia | 3/63 (5) |
| History of autoimmune disease | 25/68 (37) |
| Lupus erythematosus | 13/68 (19) |
| Rheumatoid arthritis | 4/68 (6) |
| Antiphospholipids syndrome | 4/68 (6) |
| Overlap syndrome | 2/68 (3) |
| Autoimmune cytopenia | 2/68 (3) |
| Autoimmune thyroiditis | 2/68 (3) |
| Autoimmune cytopenia | 2/68 (3) |
| Multiple sclerosis | 1/68 (2) |
| Alopecia areata | 1/68 (2) |
| Clinical abnormalities | |
| Lesions size | |
| 1-5 cm | 16/38 (42) |
| 5-10 cm | 12/38 (32) |
| >10 cm | 9/38 (24) |
| Morphology of the lesions | |
| Nodules | 53/61 (87) |
| Plaques | 16/61 (26) |
| Ulceration | 6/61 (10) |
| Number of lesions | |
| Single | 5/68 (7) |
| Multiple | 63/68 (93) |
| Localization of the lesions | |
| Upper limb | 36/68 (53) |
| Lower limb | 42/68 (62) |
| Trunk | 37/68 (54) |
| Head | 15/68 (22) |
| B symptoms | 46/67 (69) |
| Fever | 36/67 (54) |
| Weight loss | 19/67 (28) |
| Asthenia | 36/67 (54) |
| Lymphadenopathy | 21/66 (32) |
| Splenomegaly | 11/65 (17) |
| Hepatomegaly | 11/66 (17) |
| Biological abnormalities | |
| Hemophagocytic syndrome | 12/68 (18) |
| Auto-antibodies | 32/52 (62) |
| Anti-nuclear antibodies (titer > 1/80) | 30/52 (58) |
| Treatments | |
| Polychemotherapy† | 17/68 (25) |
| Polychemotherapy as first-line treatment | 11/68 (16) |
| Followed by an autologous stem cell transplantation | 4/68 (6) |
| Followed by an allogeneic stem cell transplantation | 1/68 (2) |
| Polychemotherapy as second-line treatment | 6/68 (9) |
| Followed by an autologous stem cell transplantation | 1/68 (2) |
| Followed by an allogeneic stem cell transplantation | 1/68 (2) |
| Immunosuppressive drug as first-line treatment | 52/68 (77) |
| Corticosteroids | 16/68 (24) |
| Corticosteroids + low-dose methotrexate | 12/68 (18) |
| Hydroxychloroquine | 8/68 (12) |
| Low-dose methotrexate | 7/68 (10) |
| Corticosteroids + hydroxychloroquine | 2/68 (3) |
| α-interferon | 2/68 (3) |
| Chloraminophene | 1/68 (2) |
| Corticosteroids + cyclosporine | 1/68 (2) |
Including: Vietnam (n = 4), Cambodia (n = 2), Bangladesh (n = 1), China (n = 1), not precise (n = 1)
Including the following regimen: CHOP (cyclophosphamide, adriamycin, vincristine, prednisone); CHOEP (CHOP + etoposide); ESHAP (etoposide, methylprednisolone, cisplatin, cytarabine); doxorubicin and cyclophosphamide; gemcitabine and oxaliplatin